DexCom: Exiting The 'Expansion Phase' As Competition Intensifies [Seeking Alpha]
DexCom, Inc. (DXCM)
Last dexcom, inc. earnings: 4/28 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
dexcom.com/investors
Company Research
Source: Seeking Alpha
Play 8min Summary DexCom's stock fell sharply after mixed Q2 earnings and lowering full-year guidance, signaling a revaluation phase with lower growth expectations. Revenue guidance was cut from $4.2-$4.35 billion to $4.0-$4.05 billion, indicating an 11% growth, aligning closer to the sector median. Q3 earnings were, largely, as expected and management reiterated full-year guidance. Analysts had been projecting ~15% YoY sustained revenue growth, but it is appearing that closer to high-single digit growth is more realistic. I believe that DexCom's P/E ratio remains unsuitably high (still over 40) for a company that is nearing growth similar to its sector and that the P/E ratio will continue to compress as growth expectations adjust. miodrag ignjatovic DexCom's Lower Growth Projections Signal a Revaluation Phase DexCom, Inc.'s NASDAQ: DXCM ) stock fell off a cliff in July after delivering mixed Q2 earnings and lowering full-year guidance . Prior to Q2, DexCom had cl
Show less
Read more
Impact Snapshot
Event Time:
DXCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXCM alerts
High impacting DexCom, Inc. news events
Weekly update
A roundup of the hottest topics
DXCM
News
- Money for tech that matters [TechCrunch]TechCrunch
- DexCom and OURA Ink Partnership for Metabolic Health Innovation [Yahoo! Finance]Yahoo! Finance
- Here's Why DexCom (DXCM) Declined In Q3 [Yahoo! Finance]Yahoo! Finance
- Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial [CNBC]CNBC
- Medtronic (MDT) Q2 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
DXCM
Earnings
- 10/24/24 - Miss
DXCM
Sec Filings
- 11/22/24 - Form 4
- 11/18/24 - Form 4
- 11/15/24 - Form 144
- DXCM's page on the SEC website